Trial Profile

Investigation of the Immune Response Before and After COVID-19 Disease or SARS-CoV-2 Vaccination in Dialysis Patients, Solid Organ Recipients and Medical Staff

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elasomeran (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics
Acronyms DIA-Vacc

Most Recent Events

02 Aug 2022 Planned number of patients changed from 2500 to 3500.
02 Aug 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
02 Aug 2022 Planned primary completion date changed from 15 Jul 2022 to 31 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com